This Is CFS Art Launches Online Exhibit Showcasing Artists Living with CFS/ME

[Swansea, NSW, Australia] – [3 October] – This Is CFS Art is excited to announce the launch of its new website, thisiscfs.art, a unique online space dedicated to showcasing the incredible work of artists who live with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME). This online exhibit aims to highlight the resilience and creativity of these artists, offering a meaningful outlet for their voices and stories.

CFS/ME affects millions globally, yet they tend to feel invisible. The invisibility applies to both the range of symptoms that are usually not obvious for outsiders but can be very debilitating, and the fact that CFS/ME sufferers often ‘drop out’ of their life and become invisible to society. This Is CFS Art seeks to change that by providing a way to show what it means to live with CFS/ME in a variety artworks submitted by a range of artists.

“I am committed to amplifying the voices of artists who live with CFS/ME,” said Zoe Wright, Founder of This is CFS Art. “Through this platform, I hope to make visible both the disease itself and the people living with it. At the same time, this exhibit celebrates the resilience and creativity of these artists.”

Founder Zoe Wright lives with CFS/ME herself and has found art a helpful way to express the feelings and experiences of living with a chronic condition that is so little understood.

Visit thisiscfs.art today to explore the powerful artistic expressions of those living with CFS/ME. Artists living with the condition are invited to submit their own artwork through the website.

About CFS Art: CFS Art is dedicated to showcasing the work of contemporary artists who live with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. Through this platform, CFS Art seeks to raise awareness of the condition and celebrate the incredible talent and creativity of those affected.

For more information, please visit thisiscfs.art

-Zoe Wright

Contact: Zoe Wright
Founder
www.thisiscfs.art

‘You don’t want to get better’: the outdated treatment of ME/CFS patients is a national scandal

By George Monbiot

It’s the greatest medical scandal of the 21st century. For decades, patients with ME/CFS (myalgic encephalomyelitis/chronic fatigue syndrome) have been told they can make themselves better by changing their attitudes. This devastating condition, which afflicts about 250,000 people in the UK, was psychologised by many doctors and scientists, adding to the burden of a terrible physiological illness.

Long after this approach was debunked in scientific literature, clinicians who championed it have refused to let go. They continue to influence healthcare systems, governments and health insurers. And patients still suffer as a result.

Read the full article in The Guardian HERE.

Why the Psychosomatic View on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Is Inconsistent with Current Evidence and Harmful to Patients

Abstract:

Since 1969, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) has been classified as a neurological disease in the International Classification of Diseases by the World Health Organization. Although numerous studies over time have uncovered organic abnormalities in patients with ME/CFS, and the majority of researchers to date classify the disease as organic, many physicians still believe that ME/CFS is a psychosomatic illness.
In this article, we show how detrimental this belief is to the care and well-being of affected patients and, as a consequence, how important the education of physicians and the public is to stop misdiagnosis, mistreatment, and stigmatization on the grounds of incorrect psychosomatic attributions about the etiology and clinical course of ME/CFS.
Source: Thoma M, Froehlich L, Hattesohl DBR, Quante S, Jason LA, Scheibenbogen C. Why the Psychosomatic View on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Is Inconsistent with Current Evidence and Harmful to Patients. Medicina. 2024; 60(1):83. https://doi.org/10.3390/medicina60010083 https://www.mdpi.com/1648-9144/60/1/83 (Full text)

Contesting oppressive regimes of truth: A critical feminist re-examination of (bio)psychosocial hegemony in the field of myalgic encephalomyelitis / chronic fatigue syndrome

Abstract:

Myalgic encephalomyelitis / chronic fatigue syndrome, a disabling condition disproportionately affecting women, is predominantly clinically managed through a (bio)psychosocial lens with psychosocial-inspired therapies, criticised for facilitating social and epistemic injustice, psychological and physical harms. Whilst most literature contesting (bio)psychosocial practices espouses a mainstream scientific perspective, politics and power relations undergirding psychosocial hegemony are better explicated through a critical lens. This article re-examines the ascendancy of psychosocial therapies and related practices through a critical feminist psychology and Foucauldian lens, with a view to locating oppressive practices in their socio-political and cultural context and promoting dialogue on possibilities for positive social change.

Source: Hunt, J. E. (2023, August 10). Contesting oppressive regimes of truth: A critical feminist re-examination of (bio)psychosocial hegemony in the field of myalgic encephalomyelitis / chronic fatigue syndrome. https://doi.org/10.31235/osf.io/3g7kp https://osf.io/preprints/socarxiv/3g7kp/ (Full text)

Online Health Communities in Controversy over ME/CFS and Long Covid

Abstract:

The condition known variously as myalgic encephalomyelitis, chronic fatigue syndrome, or ME/CFS has been steeped in controversy for 40 years or more. Long Covid, first noticed and named in 2020, has become entangled with the ME/CFS controversy because of striking similarities in the experiences of patients suffering from the two illnesses. Online health communities (OHCs) have played central roles in both controversies, but these are not the kinds of roles that have been so well-documented in prior literature.

While prior research has established many ways in which participation in an OHC may benefit or otherwise affect community members themselves, this essay focuses on how OHCs contribute to positional shifts in health controversies that involve other communities as well. Using a framework for understanding health controversies as argumentative polylogues, I show that OHCs arguing with other players have made contributions that are both effective in gaining ground for the OHCs’ own goals and in elevating the overall quality of the debate. Further, in some cases these contributions have been so innovative as to suggest surprising future trajectories for OHCs.

Source: Jackson, S. (2023). Online Health Communities in Controversy over ME/CFS and Long Covid. European Journal of Health Communication4(2), 49–72. https://doi.org/10.47368/ejhc.2023.203 https://ejhc.org/article/view/3559/2989 (Full text)

Long covid: protesters outside the White House demand better care

Protesters took to the pavement outside the White House on 19 September to demand a better deal for people affected by long covid, complaining that the Biden administration’s plans fell short on action and funding.

“The pandemic is over,” President Joe Biden declared the night before in a pre-recorded interview which aired on the news magazine 60 Minutes. “We still have a problem with covid,” he said. “We’re still doing a lot of work on it but the pandemic is over. If you notice, no one’s wearing masks. Everybody seems to be in pretty good shape. And, so, I think it’s changing.”

But the scene outside the presidential mansion the next day belied that message. Wearing black masks and red shirts, protesters called for research, medical treatment, and social services for those with long covid. Around half would qualify for a diagnosis of myalgic encephalomyelitis/chronic fatigue syndrome. The protest was organised by #MEAction, an international network of patient advocates.

“I went undiagnosed for 15 years, because doctors are not educated about the condition,” Jennifer Nish told The BMJ. Nish, from Lubbock, Texas, said that she was inspired to help organise the protest to raise awareness. “I don’t want anyone to go through what I had to go through,” she said and called on “the White House to treat this like the emergency that it is.”

Read the rest of this article HERE.

Source: Roehr B. Long covid: protesters outside the White House demand better care BMJ 2022; 378 :o2266 doi:10.1136/bmj.o2266  https://www.bmj.com/content/378/bmj.o2266 (Full text)

Transcript: NIH ME/CFS Advocacy Call – March 28, 2022

Transcript:

Ms. Barbara McMakin: Good afternoon everyone and thank you for standing by. My name is Barbara McMakin and I’m from the NINDS Office of Neurosciece Communications and Engagement. On behalf of the NIH, I would like to welcome you to this afternoon’s call and to thank you for your interest in participating in this discussion with us today.

Today’s call is being recorded. If you have any objections please disconnect at this time. Dr. Vicky Whittemore, Program Director at NINDS, will introduce the speakers, each of whom will make some remarks, after which we will answer your questions. If you have a question for our speakers, we invite you to submit it through the Q and A box at the bottom of the Zoom screen. We will try to make our remarks brief so that we can answer as many questions as possible in the time available to us this afternoon.

I also wanted to mention that we are exploring different formats for these telebriefings going forward. For our next telebriefing we plan to include live oral questions during the question and answer session. That telebriefing has not yet been scheduled, but once we have those details we will send out a message to the listserv and post the call information on the ME/CFS website. Now, I would like to hand the call over to Dr. Whittemore.

Read the rest of this transcript HERE.

Community Advisory Committee Develops Priorities for ME/CFS Research

Press Release:

Posted by CII Coordinator, May 10, 2022

The Community Advisory Committee (CAC) for the NIH ME/CFS Research Network was established to bridge the gap between researchers and the ME/CFS community with the goal of accelerating the pace of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) research. The CAC is a group of 15 individuals from various professional backgrounds, all of whom have lived experience of the disease.

The CAC Research Priorities working group has authored a report on the challenges and priorities to be addressed to achieve needed outcomes for people with ME/CFS. This has become especially urgent given the large number of people who already have, and are expected to develop, ME/CFS following COVID-19.

ME/CFS is a debilitating, chronic, complex disease that most often follows an infection and is associated with neurological, autonomic, immunological, and metabolic abnormalities. Patients experience a substantial impairment in functioning, and symptoms such as sleep dysfunction, cognitive impairment, orthostatic intolerance, pain, fatigue, and the hallmark post-exertional malaise (PEM), an exacerbation of symptoms following even small amounts of previously tolerated activity. An estimated 836,000 to 2.5 million Americans suffer from ME/CFS with a greater prevalence in females, adults and possibly people who are Black and Latinx. There are no validated biomarkers or FDA-approved treatments and patients can struggle to access adequate clinical care. An estimated 25% are homebound or bedbound and 75% are unable to work. Recovery is rare and patients can remain ill for decades.

Progress in understanding the etiology of ME/CFS and developing biomarkers and treatments has been constrained by a number of interrelated challenges, such as the inherent complexity and heterogeneity of the disease, inadequate study methods, challenges in collaborating across all stakeholders, misunderstanding about the nature of the disease, and lack of research funding and researchers in the field. But even with these challenges, substantial progress has been made in understanding some of the underlying pathology.

The pandemic has created the tragic opportunity to finally understand how an infection can result in chronic illness. At the same time, the knowledge and expertise gained from years of ME/CFS research has provided valuable insights for Long COVID research.

Leveraging this opportunity for ME/CFS requires ME/CFS-specific funding and a ME/CFS strategic research plan to expedite progress in ME/CFS diagnostics and treatments. It also requires the integration of learnings from ME/CFS research into the PASC strategy, not only to help accelerate research in Long COVID but to better understand ME/CFS onset, natural history, and pathology. A natural experiment is underway which cannot be replicated, and this calls for swift, decisive action before the window of opportunity to study early-onset ME/CFS closes as the pandemic resolves.

People with ME/CFS, including those who have developed ME/CFS following COVID-19, are waiting.

The CAC Research Priorities working group developed this comprehensive but concise report outlining the long-standing barriers that have constrained progress in ME/CFS and strategies for their resolution, as well as key short and longer term research priorities that need to be progressed to accelerate meaningful research and achieve outcomes for people with ME/CFS, including those whose ME/CFS developed following COVID-19. These recommendations can be used by researchers to generate new study designs and refine existing goals, facilitate collaborations between research domains and stakeholders, and by federal and private funders to guide award distribution and agenda setting.

Click here to download the CAC Research Priorities Report

The Research Priorities working group is available and eager to discuss the contents of this document with researchers. Please contact us at any time at: CAC.MECFS@gmail.com

The authors of this guide are: Mary Dimmock, Rochelle Joslyn (chair), Sabrina Poirier, Jaime Seltzer and CAC Director, Allison Kanas.

This work was supported by US Public Health Service grant 5U54AI138370 and 5U24NS105535. This content does not represent the official views of the National Institute of Neurological Disorders and Stroke or the National Institutes of Health.

AMMES WANTS YOU!

AMMES needs volunteers! AMMES is actively recruiting volunteers to help AMMES grow and prosper.

Fundraising coordinator –  should have experience fundraising for non-profits (We usually run fundraisers once or twice a year.)

IT Person – keeps website  up to date – experience with WordPress a must! (Time commitment: 1 hour a month)

Patient Advocate – ideally someone with Social Work background. Occasionally we get requests from patients who need help finding housing programs or other types of government assistance. (Time commitment:1 hour a month)

We are also looking for board members. Board members do not need to have ME/CFS, but must demonstrate knowledge about the disease and share a commitment to serve the community. Because we are a nationally-focused nonprofit, board members must be US citizens or residents.

Read more about what we do on our website HERE.

Please contact us at admin@ammes.org if you are interested in being a part of this wonderful organization.

AMMES is a 501(c)(3) national nonprofit. Your donations are tax deductible.

You can donate HERE.

The teachings of Long COVID

Long COVID is the state of not recovering several weeks following acute infection with SARS-CoV-2, whether tested or not. It is a patient-made umbrella term for this condition, which may involve multiple pathologies. The underlying mechanisms are still largely unknown, but hypotheses include inflammatory or autoimmune processes, organ damage and scarring, hypercoagulability, endothelial damage, or even persistent viral protein in the body,. Based on the UK Office for National Statistics (ONS) estimates, the prevalence of Long COVID is around 1 in 7 people at three months from the infection, and it is most common in working-age adults, but also occurs in other age groups, including children. More recent ONS figures indicate that there are 376,000 people in the UK who have had Long COVID for at least one year. It has a wide range of symptoms, but the most common are exhaustion, breathlessness, muscle aches, cognitive dysfunction, including poor memory and difficulty concentrating, headache, palpitations, dizziness and chest tightness or heaviness. The nature of the symptoms is mostly relapsing, resulting in significant dysfunction and limitations in a relatively large proportion of sufferers,.

It seemed nobody had thought about the enormous implications of chronic disease as a result of letting SARS-CoV-2 spread through the community, assuming it would all be fine for those classed as non-vulnerable.

During the past year, I have been advocating for Long COVID, as well as doing research on it. I experienced it after developing COVID-19 symptoms in March 2020. My acute illness was not severe, so I did not go to hospital, as the medical advice at the time was to isolate at home, and that, like flu-like illness, one would be completely recovered within a week or two. This also meant I did not have access to testing to confirm infection, as community testing stopped in the UK on March 12, 2020. Although I felt improvements, the illness did not go away after several weeks. Some of my symptoms, the chest heaviness, muscle aches, and fatigue, remained fluctuating for months, while new symptoms, such as palpitations, also appeared. Every time I felt it was almost over, symptoms came back. I started recognising and avoiding some of the activities that triggered the symptoms, but I could not always work out what caused the relapses.

The constant cycle of disappointment at not completely recovering was devastating. The never-ending symptoms and their effect on my daily activities were a cause for worry. It was somewhat reassuring that so many others were posting similar stories on social media, but it was a struggle to get Long COVID recognised by governments and national health agencies as a serious problem back then. It seemed nobody had thought about the enormous implications of chronic disease as a result of letting SARS-CoV-2 spread through the community, assuming it would all be fine for those classed as non-vulnerable. As I wrote in a previous piece ‘death is not the only thing to count in this pandemic, we must count lives changed’. I urged public health agencies to quantify and define Long COVID,. Over the last year, I have been engaging in forums to raise awareness on its significance, impact, and scale. I have also worked with other people living with Long COVID to research the characteristics of the illness. Through this journey, I have learnt some lessons that apply not only to Long COVID but more widely to pandemic preparedness, equality, and social justice, and how medicine and society deal with similar chronic conditions.

The first lesson was how much our understanding, as scientists or physicians, can be enriched by patient experience. This includes genuine patient involvement in all stages of science and healthcare design, but may also include us wearing the two hats of patient and expert. Unfortunately, a lot of healthcare professionals and health scientists across the world caught SARS-CoV-2 with many suffering the consequences of Long COVID. In the UK, 3.6% of all healthcare staff were estimated to have Long COVID. The experience of the illness not only brings deep understanding and appreciation of its real-life impact, but also of the questions that need answering. People with lived experience must have a central role in shaping the research and services agenda because they are experts in living with the disease. Even with substantial patient involvement in shaping care and research, some sections of society will always have more representation in decision-making forums than others. Therefore, without seeking insight and input from those usually unheard, our response will always be inadequate.

Another lesson was that we need systems in place that measure morbidity in addition to mortality. We have always been better at measuring the acute over the chronic, but it is the latter that has the most long-lasting impact on societies. At the beginning of the pandemic, long-term illness and ensuing disability due to COVID were completely dismissed and did not shape policy decisions. This is partly because they were not adequately quantified, and the models informing policy and public opinion used short-term outcomes of hospitalisation and death. It is disheartening to still frequently see recovery confused with short-term survival or hospital discharge. We need systems to record recovery and continued illness following infection, accurately and universally. Disease registers have been employed for other chronic conditions such as cancer and could prove very valuable for Long COVID as well as other post-viral illnesses.

A third lesson was that we must challenge stereotyped narratives that tend to dominate the Long COVID discourse. Long COVID has been predominately pictured as something that mainly ails middle-aged women. However, the difference in the prevalence between women and men seems relatively small (15% vs 13% according to ONS estimates). Women have experienced not being believed about their symptoms with other similar chronic conditions, such as chronic fatigue syndrome and fibromyalgia. This has the potential to lead to stigma and institutional discrimination. When the dismissal of concerns and symptoms by service providers and employers is compounded by demographic, ethnic, social, and economic pre-existing structural disparities, the injustice is exacerbated. The stigma can become internalised potentially depriving people with lived experience of Long Covid from recognition, support, and services because they do not want to face the dismissal, disbelief, and denial. We must not repeat past mistakes of stereotyping and pushing those already disadvantaged away from seeking help.

To avoid the effect of stereotyping, stigma, and variation in recognition, and to measure the effect of Long COVID on systems, the economy, and the whole of society, we need to agree case definitions as soon as possible. Science on the topic is evolving and case definitions will need to be frequently updated, but we cannot afford to wait. People living with Long COVID need proper clinical assessments, medical investigations, and a diagnosis. A diagnosis is necessary not only for treatment and rehabilitation purposes, but also to maintain livelihoods. Without it, people with what are considered ‘unexplained symptoms’ may lose out on employment rights and benefits, leading to financial hardship that can exacerbate their illness. The diagnosis could simply be an umbrella term like Long COVID that encompasses some uncertainty about how it manifests. A case definition for research can be more stringent than that for the purpose of surveillance. Criteria used for clinical diagnosis must be the most inclusive because people’s lives depend on them (11). The case definitions must be based on clinical assessment and not be dependent on laboratory tests, since there is a range of problems with these, including access, affordability, and accuracy.

Though perhaps the most important lesson that Long COVID taught me, and I hope it can teach others, is that showing humility in the face of uncertainty is the first right step to deal with a phenomenon that we do not fully understand. Throughout the pandemic, I have seen uncertainty in science, medicine and public health communicated with certainty. This has been largely damaging, and that includes the case of Long COVID. The possibility that COVID-19 might not be a short illness for all, was entirely dismissed from public communication, despite multiple examples of devastating long-lasting effects of other viruses. Assumptions have been made about the nature, cause, and mode of treatment of Long COVID, despite a lack of evidence to support them. Acknowledging we do not know everything does not mean inaction. It means informed action with honesty, which may involve applying the precautionary principle until we know more.

The pandemic is not over, and it is peaking in many parts of the world. Therefore, preventing Long COVID should be high on everyone’s agenda. Long COVID messaging must be incorporated in all prevention policies including vaccination and non-pharmacological interventions. The effect of COVID-19 vaccines in modifying the course of Long COVID is still uncertain and under investigation. In the meantime, the primary purpose of vaccination in relation to Long COVID should be to prevent it in those who do not have it, and to prevent re-infection in those who do.

As for me, I am grateful that my Long COVID has been a lighter guest in 2021, with less frequent and shorter visits. This is sadly not the story of everybody who is living with it, with many not improving, or deteriorating over time. Let us, for their sake, not repeat past mistakes and learn from the global experience of this phenomenon to help all people living with similar under-researched chronic conditions, and prevent more from happening.

Read the full article HERE.

Source: Alwan NA. The teachings of Long COVID. Commun Med (Lond). 2021 Jul 12;1:15. doi: 10.1038/s43856-021-00016-0. PMID: 35602198; PMCID: PMC9053272. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9053272/ (Full text)